Antibe Therapeutics (ATBPD) Stock Price, News & Analysis

Company Overview

Antibe Therapeutics Inc. is a clinical-stage pharmaceutical company dedicated to developing safer therapies for pain and inflammation. Leveraging its proprietary hydrogen sulfide (H2S) releasing platform, the company aims to mitigate the gastrointestinal and cardiovascular side effects commonly associated with non-steroidal anti-inflammatory drugs (NSAIDs). Antibe’s lead product candidate is Otenaproxesul, a reformulated version of naproxen designed to maintain the efficacy of traditional NSAIDs while enhancing tolerability and safety.

Founded in 2003 and headquartered in Toronto, Canada, Antibe Therapeutics operates research and development facilities in both Canada and the United States. The company has pursued a strategic development program that includes Phase II clinical trials for Otenaproxesul in osteoarthritis, acute postoperative pain and musculoskeletal injuries. In parallel, Antibe continues to explore additional pipeline candidates targeting inflammatory conditions, leveraging its H2S platform to expand into new therapeutic areas.

Antibe’s research collaborations and partnerships reinforce its commitment to scientific innovation. The company has engaged in cooperative research agreements with academic institutions and contract research organizations to validate its technology and advance clinical studies. These alliances have facilitated the development of robust preclinical data supporting the safety profile of its compounds, positioning Antibe for potential regulatory submissions in multiple jurisdictions.

Under the leadership of Chief Executive Officer Lindsay Machan, Antibe Therapeutics has strengthened its executive team with seasoned professionals in drug development, regulatory affairs and commercialization. Co-founder and Chief Scientific Officer John Wallace, Ph.D., continues to guide the scientific strategy, drawing on decades of expertise in pharmacology and gastroenterology. Together, the management team steers Antibe toward its goal of delivering next-generation therapies that address unmet needs in pain management and inflammatory disease.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.22 to $0.22
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 29,710 shs
• Market Capitalization: $1.21 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ATBPD Stock Analysis - Frequently Asked Questions

How do I buy shares of Antibe Therapeutics?

Shares of ATBPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ATBPD
• CIK: N/A
• Web: www.antibethera.com
• Phone: 416 922 3460
• Fax: N/A
• Employees: 47
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.60)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.54 million
• Net Margins: -273.96%
• Pretax Margin: N/A
• Return on Equity: -150.49%
• Return on Assets: -98.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.97
• Quick Ratio: 5.42

Sales & Book Value

• Annual Sales: $7.51 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.10 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 387,000,000
• Free Float: N/A
• Market Cap: $1.21 billion
• Optionable: Not Optionable
• Beta: 0.57